PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsLaboratoires SMB
Laboratoires SMB
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
PravafenixFenofibrate, Pravastatin2011-04-142024-2033
Hypercholesterolemia
,
Coronary artery disease
,
Dyslipidemias
,
Hypertriglyceridemia
,
Hyperlipoproteinemias
,
Periodontal diseases
,
Infectious skin diseases
,
Gram-negative bacterial infections
,
Oral candidiasis
,
Gram-positive bacterial infections
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Retinol
hyperalgesia
,
toxoplasmosis
,
flushing
,
healthy volunteers/patients
,
bacterial infections
,
dengue
,
dyslipidemias
,
rheumatoid arthritis
,
arthritis
,
atrial fibrillation
,
pancreatic neoplasms
,
psoriasis
,
osteoporosis
,
infections
,
respiratory tract infections
,
postmenopausal osteoporosis
,
neoplasm metastasis
,
bone fractures
,
malaria
,
yellow fever
,
rubella
,
iron-deficiency anemia
,
hematopoiesis
,
iron deficiencies
,
acne vulgaris
,
type 2 diabetes mellitus
,
human influenza
,
common cold
,
congenital abnormalities
,
depressive disorder
,
growth and development
,
sickle cell anemia
,
yin deficiency
,
insulin resistance
,
abdominal obesity
,
lipid metabolism
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use